Orgenesis Inc
NASDAQ:ORGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shenzhen Capol International & Associates Co Ltd
SZSE:002949
|
CN |
|
China Aircraft Leasing Group Holdings Ltd
HKEX:1848
|
HK |
|
G
|
Get Nice Financial Group Ltd
HKEX:1469
|
HK |
|
Swaraj Engines Ltd
NSE:SWARAJENG
|
IN |
|
Prataap Snacks Ltd
NSE:DIAMONDYD
|
IN |
|
Zhonghua Gas Holdings Ltd
HKEX:8246
|
HK |
Orgenesis Inc
Total Current Liabilities
Orgenesis Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orgenesis Inc
NASDAQ:ORGS
|
Total Current Liabilities
$26.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Orgenesis Inc
Glance View
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 151 full-time employees. The company went IPO on 2010-07-01. The firm is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The company has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.
See Also
What is Orgenesis Inc's Total Current Liabilities?
Total Current Liabilities
26.9m
USD
Based on the financial report for Dec 31, 2024, Orgenesis Inc's Total Current Liabilities amounts to 26.9m USD.
What is Orgenesis Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
19%
Over the last year, the Total Current Liabilities growth was 64%. The average annual Total Current Liabilities growth rates for Orgenesis Inc have been 20% over the past three years , -9% over the past five years , and 19% over the past ten years .
